M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Forest to acquire US marketing rights to Saphris for upfront USD240m and additional payments from Merck
Forest Laboratories Holdings Limited, a wholly owned subsidiary of fully integrated, specialty pharmaceutical company Forest Laboratories Inc (NYSE:FRX), announced on Monday the acquisition of exclusive rights in the US for Saphris (asenapine) sublingual tablets, a treatment for adult patients...
If you want to view the full text, you must first purchase archive credits.
Return to Archives